Jul. 12 at 10:18 PM
$EVAX Headline here this morning.
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
"The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1
EVX-V1 is a next-generation, multi-component vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens"